Quantcast

Latest Heparin Stories

2010-09-02 08:46:25

(Ivanhoe Newswire) "“ Many coronary procedures are done every year, and many involve the use of Heparin, an anticoagulant which prevents the blood from clotting and forming harmful bigger clots in the veins and arteries. It is typically used in lower doses for patients getting coronary procedures, but this study shows that using lower doses isn't more effective than using normal dosage. Patients with acute coronary syndrome initially treated with Fondaparinux, an anticoagulant which...

2010-08-31 20:33:20

Patients with acute coronary syndromes initially treated with the anticoagulant fondaparinux who underwent a coronary procedure (such as balloon angioplasty) and received a lower dose of the anticoagulant heparin during the procedure did not have a reduced rate of major bleeding and vascular access site complications, according to a study that will appear in the September 22 issue of JAMA. The study is being released early online to coincide with its presentation at the European Society of...

2010-08-31 20:29:37

A landmark international study, coordinated by McMaster University, has found that lower doses of a blood thinner called unfractionated heparin (UFH) during angioplasty did not reduce bleeding or vascular complications compared to standard dose UFH in patients initially treated with a blood thinner, fondaparinux. In a prior study, the OASIS 5 trial, researchers from McMaster University showed that a blood thinner fondaparinux compared to another blood thinner, enoxaparin, reduced serious...

2010-08-03 07:30:00

BEDFORD, Mass., Aug. 3 /PRNewswire/ -- Instrumentation Laboratory (IL) today announced the release of the new HemosIL HIT-Ab(PF4-H) assay as a European CE IVD Mark product under the European Directive on In Vitro Diagnostic Medical Devices. Delivering results in minutes, the HemosIL HIT-Ab(PF4-H) assay detects total immunoglobulin against Platelet Factor 4-Heparin complexes, the antibodies associated with the pathology of HIT. (Logo:...

2010-07-26 15:05:00

BASKING RIDGE, N.J., July 26 /PRNewswire/ -- Regado Biosciences, Inc., a privately held biopharmaceutical company pioneering the development of a novel two-component antithrombotic drug technology consisting of therapeutic aptamers with their matched active control agents, announced publication of results from a Phase 2a study for its lead compound, the REG1 system. The study is known as REVERSAL-PCI. The company's REG1 technology, a selective coagulation factor IXa inhibiting aptamer...

2010-07-26 07:30:00

BEDFORD, Mass., July 26 /PRNewswire/ -- Instrumentation Laboratory (IL), today announced it will host an ILluminations webinar on HIT, to be held on Thursday, October 7, 2010 from 2:00 p.m. to 3:00 p.m. (Central European Time). This web-based, Continuing Education seminar will feature Andreas Greinacher, M.D., presenting "Laboratory and Clinical Aspects of HIT." The essential components for successful implementation and management of a HIT testing program will be discussed. HIT is a...

2010-07-23 14:50:00

NOTE TO EDITORS: In response to multiple questions about the product's indications, the press release was revised to clarify that Sandoz's enoxaparin soldium for injection was approved for all of the same indications as Lovenox. SILVER SPRING, Md., July 23 /PRNewswire-USNewswire/ -- The U.S. Food and Drug Administration today approved the first generic version of Lovenox (enoxaparin sodium injection), an anti-coagulant drug used for multiple indications, including prevention of deep vein...

2010-07-23 09:48:00

SILVER SPRING, Md., July 23 /PRNewswire-USNewswire/ -- The U.S. Food and Drug Administration today approved the first generic version of Lovenox (enoxaparin sodium injection), an anti-coagulant drug used to prevent deep vein thrombosis (DVT), a potentially deadly blood clotting condition. (Logo: http://photos.prnewswire.com/prnh/20090824/FDALOGO) (Logo: http://www.newscom.com/cgi-bin/prnh/20090824/FDALOGO) Approved for use in 1993, Lovenox is made from heparin, a blood-thinning drug whose...

2010-07-12 10:48:00

BETHLEHEM, Pa., July 12 /PRNewswire/ -- B. Braun Medical Inc. (B. Braun) announced today the availability of large volume heparin infusion solutions. (Logo: http://photos.prnewswire.com/prnh/20081022/NYW008LOGO ) (Logo: http://www.newscom.com/cgi-bin/prnh/20081022/NYW008LOGO ) Based on the new United States Pharmacopeia (USP) standards for heparin products released by the U.S. Food and Drug Administration (FDA) in October 2009, changes to B. Braun's large volume heparin IV solutions...

2010-07-09 14:33:50

McMaster University researcher leads international study An ultra-low-molecular-weight heparin called semuloparin has been found to reduce the incidence of venous thromboembolism in orthopedic surgery patients in a large clinical program being lead by a steering committee chaired by McMaster University professor Dr. Alexander Turpie. The follow-up analysis of three recently completed international clinical studies on short-term venous thromboembolism (VTE) protective medicine in patients...


Word of the Day
penuche
  • A fudgelike confection of brown sugar, cream or milk, and chopped nuts.
'Penuche' is a variant of 'panocha,' a coarse grade of sugar made in Mexico. 'Panocha' probably comes from the Spanish 'panoja, panocha,' ear of grain.
Related